...good story on SLCA.
Top 4 Large-Cap Stocks In The Independent Oil & Gas Industry With The Highest EPS Estimates For The Next Quarter
Last update: 04/03/2014 4:09:55 am
Below are the top large-cap independent oil & gas stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next quarter.
EOG Resources (NYSE: EOG) is likely to earn $2.29 per share in the June quarter. EOG's trailing-twelve-month revenue is $14.46 billion.
Occidental Petroleum (NYSE: OXY) is estimated to post earnings of $1.72 per share in the June quarter. Occidental Petroleum's trailing-twelve-month operating margin is 44.23%.
Continental Resources (NYSE: CLR) may earn $1.65 per share in the June quarter. Continental Resources' PEG ratio is 0.53.
Apache (NYSE: APA) is expected to earn $1.61 per share in the June quarter. Apache's trailing-twelve-month ROE is 6.86%.
...$40-plus coming up.
Sinovac Biotech has submitted a Clinical Trial Application with the China FDA to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29. Once the CTA is approved, Sinovac is prepared to initiate the clinical trials in a timely manner.
...looking good for Sinovac investors.
...if so we could see $15-$17 pps. getting interesting now.
it would be nice to see at least $7.50 this week if the face of a weak market. any good news on the flu front will make SVA rally...
...wished i did have some influence. i would have it go to $30 this week. oh, by the way the L in my middle name stands for Loves. Theo Loves Profit... sorry if that don't fit your profile of me...
Theo L. Profit
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease) and filed the new drug application with China Food & Drug Administration. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.